Clarivate

APRIL 19, 2024

2022 Jan;161:108-118 [7] Marrero JA, Ahn J, Rajender Reddy K; Americal College of Gastroenterology. CA Cancer J Clin. 2021 May;71(3):209-249 [6] Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, Wei W, Lemmens VEPP, Soerjomataram I. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer.

Medical 59

Medical Patients Specialization Healthcare 59

European Pharmaceutical Review

DECEMBER 19, 2023

Li AB, Kluge JA, Guziewicz NA, et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med. 2010;2(19):ra12. Silk-based stabilization of biomacromolecules. J Control Release. 2015;10(219):416-430.

Distribution 99

Distribution Manufacturing Food Specialization 99

European Pharmaceutical Review

JULY 5, 2022

Perez EA, Hillman DW, Mailliard JA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol, 1999; 17(6):1815-1824. Randomized Phase II Study of Two Irinotecan Schedules for Patients with Metastatic Breast Cancer Refractory to an Anthracycline, a Taxane, or both.

Patients 83

Patients Food and Drug Administration Side effects Safety 83

European Pharmaceutical Review

FEBRUARY 28, 2023

López-Rodríguez R, McManus JA, Murphy NS, et al. Questions and Answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products. EMA/409815/2020 Rev.13. Org Proc Res Dev. 2020; 24(9): 1558–1585. Cross KP, Ponting DJ.

Food and Drug Administration 87

Food and Drug Administration Pharmaceutical FDA Medicine 87

Clarivate

OCTOBER 10, 2022

14] Bex A, Uzzo R, Karam JA, et al. Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial. Annals of Oncology. 2022;33(suppl_7): S808-S869. DOI: 10.1016/annonc/annonc1089. [14]

Marketing 52

Marketing Safety Patients Competition 52

European Pharmaceutical Review

JUNE 28, 2022

Zwart MP, Hemerik L, Cory JS, de Visser JA, Bianchi FJ, Van Oers MM, et al. Characterization of H5N1 influenza virus quasispecies with adaptive hemagglutinin mutations from single-virus infections of human airway cells. 2018;92(11):e02004-17. An experimental test of the independent action hypothesis in virus-insect pathosystems.

Distribution 90

Distribution Government Media Networking 90